The US Food and Drug Administration (FDA) has approved a high-dose version of Novo Nordisk’s obesity drug Wegovy.

The Food and Drug Administration on Thursday approved a higher-dose version of Novo NordiskPopular weight loss injection Wegovy, as the company seeks to regain market share from its main competitor Eli Lilly.

Novo expects to launch the higher 7.2-milligram dose of Wegovy in April. The Danish drugmaker is positioning this version to better compete with Lilly’s obesity drug Zepbound, which has proven to be more effective at promoting weight loss than the standard 2.4-milligram dose of Wegovy.

This high efficacy has helped Zepbound become the obesity drug of choice among prescribers and patients, even though it entered the US market later than Wegovy, and has cemented Lilly’s position as the dominant player in the space.

Wegovy’s high dose helped obese patients lose an average of 20.7% of their weight after 72 weeks in a phase 3 trial. The standard 2.4 milligram dose of Wegovy showed an average of 15% weight loss in clinical trials.

“I think this makes it more competitive, and really reduces the deltas there,” Dr. Jason Britt, Novo Nordisk’s chief medical officer, said in an interview Thursday before the approval.

“But more importantly, I think it gives patients another option if they’re not reaching their goals, and it does achieve some significant weight loss for some patients,” he added.

In a separate phase 3 trial in patients with obesity and type 2 diabetes, high-dose Wegovy showed a median weight loss of 14.1%. People with diabetes usually have a harder time losing weight than people without the condition.

This marks the first approval of a GLP-1 treatment under the FDA’s new National Priority Voucher plan, which aims to reduce drug review times to one to two months for companies that the agency says support America’s national health priorities. The US Food and Drug Administration launched the pilot plan in June.